Literature DB >> 2263652

Microinjections of a nicotinic agonist into dopamine terminal fields: effects on locomotion.

E Museo1, R A Wise.   

Abstract

Nicotine induces locomotion, a behavior associated with the mesocorticolimbic dopamine system. The present study determined the effects on locomotion of direct microinjections of the nicotinic agonist cytisine into four DA terminal fields were nicotinic receptors have been localized: nucleus accumbens (NAS, n = 20), caudate putamen (CPU, n = 9), olfactory tubercle (OT, n = 8), and medial prefrontal cortex (MPC, n = 12). Male Long-Evans rats were injected with cytisine (0.1, 1, 10 and 100 nanomoles per 0.5 microliters per side) or vehicle through indwelling cannulae, and locomotor activity was recorded during a 60-minute test session; each animal was tested with each dose in counterbalanced order. NAS injections of the three highest doses of cytisine increased locomotion relative to vehicle injections; injections in the CPU, dorsal to the NAS, were ineffective, as were MPC and OT injections. The data support the notion that systemic nicotine may interact with dopaminergic projections to the NAS to produce increases in locomotor activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2263652     DOI: 10.1016/0091-3057(90)90050-r

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  10 in total

1.  Executive and social behaviors under nicotinic receptor regulation.

Authors:  Sylvie Granon; Philippe Faure; Jean-Pierre Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-22       Impact factor: 11.205

2.  The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine.

Authors:  W A Corrigall; K B Franklin; K M Coen; P B Clarke
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Influence of chronic administration of antidepressant drugs on mRNA for galanin, galanin receptors, and tyrosine hydroxylase in catecholaminergic and serotonergic cell-body regions in rat brain.

Authors:  Molly L Rovin; Katherine A Boss-Williams; Reid S Alisch; James C Ritchie; David Weinshenker; Charles H K West; Jay M Weiss
Journal:  Neuropeptides       Date:  2012-02-10       Impact factor: 3.286

4.  Effects of environmental conditioning on the development of nicotine sensitization: behavioral and neurochemical analysis.

Authors:  M S Reid; L B Ho; S P Berger
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

5.  Is the dopaminergic system involved in the central effects of nicotine in mice?

Authors:  M I Damaj; B R Martin
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Influence of tetrodotoxin and calcium on changes in extracellular dopamine levels evoked by systemic nicotine.

Authors:  M E Benwell; D J Balfour; H M Lucchi
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Characteristics of tail-tremor induced by nicotine in rats.

Authors:  K Suemaru; R Oishi; Y Gomita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

8.  5HT3 receptor antagonists do not block nicotine induced hyperactivity in rats.

Authors:  B Arnold; K Allison; S Ivanová; P R Paetsch; T Paslawski; A J Greenshaw
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

9.  Blockade of NMDA receptors in the prefrontal cortex increases dopamine and acetylcholine release in the nucleus accumbens and motor activity.

Authors:  Alberto Del Arco; Gregorio Segovia; Francisco Mora
Journal:  Psychopharmacology (Berl)       Date:  2008-08-28       Impact factor: 4.530

10.  Novel strains of mice deficient for the vesicular acetylcholine transporter: insights on transcriptional regulation and control of locomotor behavior.

Authors:  Cristina Martins-Silva; Xavier De Jaeger; Monica S Guzman; Ricardo D F Lima; Magda S Santos; Christopher Kushmerick; Marcus V Gomez; Marc G Caron; Marco A M Prado; Vania F Prado
Journal:  PLoS One       Date:  2011-03-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.